Last reviewed · How we verify

NCT03621111: IM-ADHERENCE

A Trial on the Role of Community Pharmacist in Improving Adherence and Clinical Outcomes in Post-Infarction

Status unknown NA Last updated 8 August 2018
What this trial tests

NA trial testing Patient-counseling in Myocardial Infarction, Acute in 120 participants. Status unknown.

Timeline
19 February 2018
Primary endpoint
19 February 2019
19 August 2019

Quick facts

Lead sponsorAzienda ULSS 5 Polesana
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment120
Start date19 February 2018
Primary completion19 February 2019
Estimated completion19 August 2019
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Azienda ULSS 5 Polesana

Who can join

18 and older, any sex, with Myocardial Infarction, Acute or ST Segment Elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this pilot study is to evaluate the effectiveness of the active involvement of Community Pharmacists in improving adherence to medical prescriptions in patients with acute myocardial infarction (AMI), reducing the rate of adverse events and / or re-admissions due to cardiovascular disease and reducing overall health costs. The Hospital and Community Pharmacists will collaborate with each other, the patients, heart specialists and primary care physicians, throughout 12 months from the hospital discharge.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Myocardial Infarction, Acute

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03621111.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing